Engility Awarded Prime Position on Multiple Award Contract to Support Joint Program Executive Office
Engility Awarded Prime Position on Multiple Award Contract to Support Joint Program Executive Office for Chemical and Biological Defense
CHANTILLY, Va.--(BUSINESS WIRE)-- Engility Holdings, Inc. (NYS: EGL) has been selected as a prime contractor on four domain areas of a multi-million dollar contract to support the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) headquartered at Edgewood Area, Aberdeen Proving Grounds MD. The potential value of this six-domain indefinite delivery/indefinite quantity contract is $495 million for all awardees, if all options are exercised.
For this new award, Engility was selected to provide services in the four domains of engineering and technical support, business and analytical assistance, information technology and logistics. These awards are part of JPEO-CBD's ongoing requirement for Omnibus Program, Engineering and Technical Support services. Support will be provided across the JPEO-CBD enterprise in support of acquisition program activities ongoing in the National Capital Region, San Diego, CA, and other locations across the United States.
"The JPEO-CBD continues to be an important partner for Engility and we are honored to be chosen for this award," said Engility President and CEO Tony Smeraglinolo. "This selection recognizes the history of Engility's past success supporting such a critical mission area and we look forward to the opportunity to expand our support across the Department of Defense Chem-Bio community in the future."
About Engility Corporation
Engility is a pure-play government services contractor providing highly skilled personnel wherever, whenever they are needed in a cost-effective manner. Headquartered in Chantilly, Virginia, Engility is a leading provider of systems engineering services, training, program management, and operational support for the U.S. Government with about 7,800 employees worldwide and estimated sales of $1.6 billion for 2012. To learn more about Engility, please visit www.engilitycorp.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Engility's future prospects, projected financial results, and business plans. Words such as "may," "will," "should," "likely," "anticipates," "expects," "intends," "plans," "projects," "believes," "estimates" and similar expressions are also used to identify these forward-looking statements. These statements are based on the current beliefs and expectations of Engility's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Factors that could cause Engility's actual results to differ materially from those described in the forward-looking statements can be found under the heading "Risk Factors" in the Information Statement included in our Registration Statement on Form 10, as amended, and Quarterly Report on Form 10-Q for the quarter ended September 28, 2012, which have been filed with the Securities and Exchange Commission (SEC) and are available on Engility's website (http://www.engilitycorp.com/investor-relations.html) and on the SEC's website (www.sec.gov). Forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, historical information should not be considered as an indicator of future performance.
KEYWORDS: United States North America Virginia
The article Engility Awarded Prime Position on Multiple Award Contract to Support Joint Program Executive Office for Chemical and Biological Defense originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.